Biopharmaceuticals

Shanghai – September 11, 2026 -- Natural Field has extended its NF TriSolve® nutraceutical solutions platform into the sleep wellness category with the launch of the NF TriSolve® SleepRestore complex.

New complex combines multiple functional ingredients for sleep-focused formulations

The SleepRestore complex integrates several functional components within a single formulation concept designed for nutraceutical applications targeting sleep. The launch marks Natural Field's entry into the expanding sleep wellness market, built on a solutions-oriented development approach rather than single-ingredient focus.

Delray Beach – – September 11, 2026 -- The global carboxymethylcellulose calcium market will grow from $0.06 billion in 2026 to $0.09 billion by 2036, expanding at a compound annual growth rate of 4.8%, according to a new MarketsandMarkets forecast.

Asia Pacific emerges as the fastest-growing regional market through 2036

Asia Pacific is projected to post the highest CAGR of 5.2% over the forecast period, driven by expanding pharmaceutical manufacturing in China and India, rising generic drug output, and growing contract manufacturing activity. Well-established supply chains in both countries are reinforcing cost-efficient production and rising domestic consumption of cellulose-based excipients.

Tel Aviv – – September 11, 2026 -- The Israel National Biotech Innovation Center (INBI) officially launched operations, uniting 15 of Israel's top universities, research institutions and healthcare organizations under a single translational platform for the first time.

Anat Cohen-Dayag Takes Helm of INBI Core

Anat Cohen-Dayag, PhD, Executive Chairperson of Compugen and formerly its President and CEO for 15 years, has been appointed Chief Executive Officer of INBI Core Ltd., the wholly owned operational subsidiary of INBI. Samuel Moed, former Senior Vice President of Corporate Strategy at Bristol Myers Squibb, will chair both INBI and INBI Core.

Rockville, Maryland – September 11, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.

REGENXBIO confirms back-to-back fireside chats on September 15 and 16

The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.

Hong Kong – September 11, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) has initiated a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist for obesity, after securing Investigational New Drug clearance from the FDA.

Trial enrolls 86 participants to test safety and dosing

The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ASC36 across single and multiple ascending oral doses in 86 participants with obesity (BMI ≥ 30.0 kg/m2) or overweight status (BMI ≥ 27.0 kg/m2). This marks the fourth Phase I peptide study Ascletis has launched in 2026.

Burlington, N.C. – September 11, 2026 -- Labcorp (NYSE: LH) has acquired MLM Medical Labs, a central and specialty laboratory provider with operations in the United States, Germany and South Africa, financial terms undisclosed.

Labcorp becomes the only central lab provider with wholly owned facilities on four continents

The deal extends Labcorp's laboratory footprint across North America, Europe, Asia and Africa, combining its global scale with MLM's regional laboratory network and biomarker testing capabilities. The transaction strengthens Labcorp's position as an independent central laboratory services provider for clinical trial sponsors.

Sugar Land, Texas – September 11, 2026 -- QuVa Pharma, Inc. has acquired a portfolio of essential sterile compounded medications from Central Admixture Pharmacy Services, Inc. (CAPS) after CAPS decided to exit the 503B sterile compounding business, the companies announced.

QuVa to phase in acquired products starting later in 2026

QuVa expects to begin introducing selected products from the acquired portfolio in phases later in 2026, with plans to expand offerings over the following six months. The deal covers critical medication categories including Cardioplegia, Total Parenteral Nutrition and Heparin.

Cambridge, Massachusetts – September 11, 2026 -- Harbour BioMed (HKEX: 02142) and partner Windward Bio reported positive Phase 2 interim results for HBM9378/WIN378, a twice-yearly TSLP-blocking antibody, from the 147-patient POLARIS-1 asthma trial, clearing the path for two Phase 3 studies.

Interim data show up to 174 mL lung-function gain after single dose

The Phase 2 interim analysis, conducted on the first 98 of 147 enrolled patients with uncontrolled moderate-to-severe asthma, found FEV1 increases of up to 174 mL, with a placebo-adjusted mean increase of 256 mL (p=0.033) at Week 24 after a single dose.

Biomarkers for airway inflammation drop sharply

FeNO fell by up to 24 ppb, a 43% reduction (p=0.006), while blood eosinophil counts dropped by up to 200 cells/μL, a 51% decline (p0.0001). Near-maximal effects appeared as early as Week 2 and were sustained through Week 24.

Laval – September 11, 2026 -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and Belgian biotech YUN have expanded their strategic partnership to Mexico and additional EMEA markets, building on a 2025 launch in Poland.

Partnership adds five new markets across EMEA and Latin America

The collaboration has extended YUN's acne-prone and eczema-prone skincare lines into the Czech Republic, Slovakia, Ukraine and Bulgaria, alongside a fresh entry into Mexico. A further rollout in Kazakhstan is expected in October 2026.

Poland launch deepens into eczema care after 2025 acne debut

In Poland, Bausch Health broadened its dermatology portfolio with YUN's eczema-focused skincare, following last year's introduction of the company's probiotic-based acne-prone skin products.

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

CEO Kelvin Cooper to hold one-on-one investor meetings during three-day conference

Kelvin Cooper, Ph.D., chief executive officer of the clinical-stage biotechnology company, will deliver a virtual presentation and conduct one-on-one meetings with registered investors and potential partners. The sessions will cover Lakewood-Amedex's business and clinical development strategy, recent corporate achievements, and anticipated milestones.